Evidence map›Paper›PMID 39129860›Full record

ArticleSensors & diagnostics2024

CRISPR/Cas13a-assisted amplification-free miRNA biosensor

Jae-Jun Kim, Jae-Sang Hong, Hyunho Kim, Moonhyun Choi, Ursula Winter, Hakho Lee, Hyungsoon Im

Abstract read
In one paragraph

Article in Sensors & diagnostics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jae-Jun KimCenter for Systems Biology, Massachusetts General Hospital Boston MA 02114 USA im.hyungsoon@mgh.harvard.edu +1 617 643 5679.ORCID https://orcid.org/0000-0003-0722-3402
Jae-Sang HongCenter for Systems Biology, Massachusetts General Hospital Boston MA 02114 USA im.hyungsoon@mgh.harvard.edu +1 617 643 5679.
Hyunho KimCenter for Systems Biology, Massachusetts General Hospital Boston MA 02114 USA im.hyungsoon@mgh.harvard.edu +1 617 643 5679.
Moonhyun ChoiCenter for Systems Biology, Massachusetts General Hospital Boston MA 02114 USA im.hyungsoon@mgh.harvard.edu +1 617 643 5679.
Ursula WinterCenter for Systems Biology, Massachusetts General Hospital Boston MA 02114 USA im.hyungsoon@mgh.harvard.edu +1 617 643 5679.
Hakho LeeCenter for Systems Biology, Massachusetts General Hospital Boston MA 02114 USA im.hyungsoon@mgh.harvard.edu +1 617 643 5679.ORCID https://orcid.org/0000-0002-0087-0909
Hyungsoon ImCenter for Systems Biology, Massachusetts General Hospital Boston MA 02114 USA im.hyungsoon@mgh.harvard.edu +1 617 643 5679.ORCID https://orcid.org/0000-0002-0626-1346

Funding

Development of plasmon-enhanced biosensing for multiplexed profiling of extracellular vesiclesR01GM138778 · NIGMS · MASSACHUSETTS GENERAL HOSPITAL · PI IM, HYUNGSOON · 2020 to 2024
$2.3M
Nano-plasmonic technology for high-throughput single exosome analysesR21CA217662 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI IM, HYUNGSOON · 2019 to 2021
$585k
NCI NIH HHS R21 CA217662NIGMS NIH HHS R01 GM138778
6 · The paper itself

Abstract

MicroRNAs (miRNAs) are short (about 18-24 nucleotides) non-coding RNAs and have emerged as potential biomarkers for various diseases, including cancers. Due to their short lengths, the specificity often becomes an issue in conventional amplification-based methods. Next-generation sequencing techniques could be an alternative, but the long analysis time and expensive costs make them less suitable for routine clinical diagnosis. Therefore, it is essential to develop a rapid, selective, and accurate miRNA detection assay using a simple, affordable system. In this work, we report a CRISPR/Cas13a-based miRNA biosensing using point-of-care dark-field (DF) imaging. We utilized magnetic-gold nanoparticle (MGNPs) complexes as signal probes, which consist of 200 nm-sized magnetic beads and 60 nm-sized gold nanoparticles (AuNPs) linked by DNA hybridization. Once the CRISPR/Cas13a system recognized the target miRNAs (miR-21-5p), the activated Cas13a cleaved the bridge linker containing RNA sequences, releasing 60 nm-AuNPs detected and quantified by a portable DF imaging system. The combination of CRISPR/Cas13a, MGNPs, and DF imaging demonstrated amplification-free detection of miR-21-5p within 30 min at a detection limit of 500 attomoles (25 pM) and with single-base specificity. The CRISPR/Cas13a-assisted MGNP-DF assay achieved rapid, selective, and accurate detection of miRNAs with simple equipment, thus providing a potential application for cancer diagnosis.

Identifiers

PMID39129860
PMCPMC11308380

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.